Kornimate/medical-research-clean huggingface dataset:
prospective assessment of efficacy and safety of drug eluting stents

Conditions: Coronary Heart Disease

Summary: coronary heart disease (chd) pose a serious health threat to population. pci using drug eluting stents (des), as a well-proved and booming measure in chd management, is invasive and of high cost, however the knowledge about the real-life des use and the efficacy and safety in china is limited. by consecutively recruiting first-ever pci patients in 30 geographically representative highest-rank hospitals, this study will examine the prognosis in groups with different brands of des, and various real-life factors, that may affect patients recovery after the procedure. evidence for clinical practice and health resource allocation will be established based on the findings, to improve patients outcomes in future finally.

in this study, 6000 patients who underwent the first-ever drug eluting stents (des) deployment during the index hospitalization will be consecutively recruited in 30 tertiary hospitals scattered all over china. at study entry, participants will be interviewed during their index hospitalization, to collect information about symptoms, functioning, quality of life, and medical care. demographic characteristics, medical history, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be abstracted from medical records by well trained professional abstractors. and cag imaging will be reviewed by national and international expert panels. at 1 month, 6 month, and 12 month after discharge, participants will return to the clinic for follow up visits, a face-to-face interview will be conducted to get information about clinical events, symptoms, functioning, quality of life, and medical care during the recovery period. at 1-month and 12-month follow-up visit, blood and urine sample will be collected. participants' blood samples will be stored for future biologic and genetic studies. this study will examine the prognosis in groups with different brands of des, and various real-life factors, that may affect patients recovery after the procedure. evidence for clinical practice and health resource allocation will be established based on the findings, to improve patients outcomes in future finally.

Eligibility criteria:
inclusion criteria: * at least one des is implanted successfully in the procedure * only one of the five major brands of des is used in the procedure exclusion criteria: * prior stent implantation history

Keywords: coronary heart disease percutaneous coronary intervention drug eluting stents
treatment of aphtous ulcers with photodynamic therapy

Conditions: Oral Ulcer; Aphthous Recurrent Ulcers

Summary: the search for methods that can shorten the treatment process of aphthous ulcers, the etiology of which is not fully understood, continues. the aim of this study was to determine whether photodynamic therapy (pdt) is a clinically effective alternative in the treatment of oral aphthous ulcers.

after sample size calculation, photodynamic therapy and control groups were formed with 15 patients with aphthous ulcer in each group. laser therapy with indocyanine green was applied to the photodynamic therapy group on the day they were admitted to the clinic. no treatment was performed in the control group and only follow-up was performed. lesion diameters, pain intensity and degree of improvement at the end of 1 week were recorded in all patients.

Eligibility criteria:
inclusion criteria: * asa-1 patients without any systemic disease, * with a history of canker sores not exceeding 2 days, * not taking any antibiotics or anti-inflammatory drugs. exclusion criteria: * laser therapy contraindicated, * pregnancy, * smoking habbit, * poor oral hygiene, * patients under 18 years of age

Keywords: photodynamic therapy aphtous ulcer indocyanine green
taste changes with bariatric surgery

Conditions: Taste, Altered

Summary: it is commonly believed that a link exists between bmi and taste perception. one group of researchers observed that women who are obese experience reduced taste sensitivity when compared to normal-weight controls. others have compared taste sensitivity between lean and obese subjects and found no significant differences. the inconsistencies in these studies demonstrate how much variation in taste sensitivity is possible when different factors are applied in research. throughout several studies, one element remains constant - bariatric surgery causes appetite aversions. these changes in appetite and food preference likely have a large influence on the overall magnitude of post-surgical weight loss. although many studies have investigated the changes in taste preference after bariatric surgery, few, if any, have focused on changes in sweet taste perception.

the overall goal of the present project is to determine how future bariatric surgery will affect the taste for sweet liquids. taste perception will be assessed before surgery (pre-operative, pre-op) and after bariatric surgery, at approximately 1 month. taste studies will be conducted with solutions prepared freshly before each test using sucrose dissolved in distilled water. six concentrations of sucrose (table sugar) will be tasted in random order, with the most concentrated solution being roughly the sweetness of soda. the subject is blinded to the concentrations. it is hypothesized that there will be no significant difference in taste perception when pre-op and post-op values are compared. however, the investigators hypothesize that taste preference will identify solutions with lower concentrations post-op.

Eligibility criteria:
inclusion criteria: * women who plan to undergo bariatric surgery. * age: 21-70y. * non-smokers (at least 3 months post smoking cessation). * non-diabetic or prediabetic exclusion criteria: * subject on a medication known to affect taste perception: antibiotics, thyroid medications, psychotropic, neurological, and cardiac medications. * inability to understand the test instructions. * subject has already undergone bariatric surgery

Keywords: taste perception bariatric surgery taste preference weight loss surgery
celecoxib for reducing morphine requirement after thyroid surgery: a randomized controlled trial

Conditions: Postoperative Pain; Thyroidectomy; Cyclooxygenase 2 Inhibitors

Summary: the purpose of this study is to determine whether celecoxib is effective in the treatment postoperative pain after thyroidectomy. the research hypothesis: there is a difference in postoperative morphine consumption in the first 24 hours after thyroidectomy between patients who received celecoxib or placebo.

postoperative pain has been concerned in the past few years by both the anesthesiologists ans the surgeons. cox2-inhibitors have played an important roles in postoperative pain with minimal side effects. comparison(s): there is a difference in postoperative morphine consumption in the first 24 hours after thyroidectomy between patients who received celecoxib and placebo.

Eligibility criteria:
inclusion criteria: 1. patient asa physical status i-iii. 2. scheduled for an elective thyroidectomy. 3. body weight \> or = 40kg 4. can operate a patient-controlled analgesia (pca) device. exclusion criteria: 1. history of asthma, acute rhinitis, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or other nsaids. 2. known hypersensitivity to morphine or sulfonamides. 3. history of hepatic dysfunction. 4. creatinine clearance \< 30ml/min. 5. history of bleeding tendency. 6. history of gastrointestinal bleeding or active peptic ulcer. 7. known case of inflammatory bowel disease. 8. patient with severe heart failure.

Keywords: celecoxib postoperative pain thyroidectomy
validation of the ani in perpubescent patients in pediatric intensive care unit.

Conditions: Pain; Pediatric ALL

Summary: the ani monitor is a medical device allowing to measure the response of the autonomic nervous system to a painful stimulus. in the pediatric population under general anesthesia, the ani score can detect failure of locoregional anesthesia; ani decreases after painful stimulation during surgery, more markedly with smaller doses of remifentanil. to date, measurement of ani in sedated children in pediatric intensive care has not been performed or validated as a method of assessing pain and discomfort.


Eligibility criteria:
inclusion criteria: * prebubescent chilren (up to 2 years old) admited in picu sedated, ventilated exclusion criteria: * non sinusal rythm * atropine * pace-macker

Keywords: intensive care units, pain measurement ani, analgesia nociception index pediatric,
doravirine dose optimisation in pregnancy

Conditions: HIV

Summary: a randomised, open label, controlled pk standard of care vs doravirine plus 2 nucleoside reverse transcriptase inhibitors backbone in pregnant women initiating combination antiretroviral therapy in the second trimester of pregnancy.

women diagnosed hiv positive in the second trimester of pregnancy in south africa will be enrolled and randomised 1:1 to receive standard of care or doravirine plus 2 nrti backbone. participants will receive study treatment until delivery and up to 28 weeks postpartum, with a maximum total of 14 months of study treatment. given the high prevalence of nnrti resistance, alternative arv treatment options are essential. doravirine is licenced for the treatment of hiv-1 in adults in north america and europe. whilst the efficacy and safety of doravirine has been established in non-pregnant adults, there are no adequate human data available to establish whether dor poses a risk to pregnancy outcomes. it is important to have data on the safety and pharmacokinetics of the drug during pregnancy and in particularly the third trimester of pregnancy in order to support its use. the hypothesis for this study is that pregnancy influences the pharmacokinetics of doravirine when initiated in the second trimester.

Eligibility criteria:
inclusion criteria: * women ≥ 18 years old * ability to give informed consent prior to participation * willing and able to comply with all study requirements * hiv positive * pregnant (initiating cart ≥ 12 weeks and \< 26 weeks gestation) * intention to breastfeed postpartum exclusion criteria: * received any cart in preceding 6 months * chronic hepatitis b (hbv) infection with clinical evidence of transaminitis * elevations in serum levels of alanine aminotransferase (alt) \> 5 times the upper limit of normal (uln) or alt \> 3xuln and bilirubin \>2xuln (with \> 35 % direct bilirubin) * previous documented failure of an nnrti-containing cart regimen * previous history of hypersensitivity to any arv * concomitant medication which are inducers of soc and dor metabolism (e.g. rifampicin, anti-epileptic agents, rifabutin, st john's wort, mitotane, enzalutamide, lumacaftor). contraindicated medications can be found on liverpool drug interactions website (hiv-druginteractions.org) * participants with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption cannot take dor as the tablet contains lactose monohydrate * clinical depression or clinical judgment suggests increased risk of suicidality

Keywords: pregnancy
a study to determine if antibiotics prevent infection in the pancreas of patients where part of the pancreas has died

Conditions: Pancreatitis, Acute Necrotizing

Summary: this is a research study in patients having a condition known as necrotizing pancreatitis. this is inflammation of the pancreas (an intestinal organ which assists with digestion) that has resulted in the damage and death of some pancreatic tissue. this damaged pancreatic tissue may develop a bacterial infection, which can cause further -sometimes very serious- health problems. it may be possible to prevent or delay infection by giving 'prophylactic' antibiotics (that is - to provide protection before any infection starts). however, it is not certain that this antibiotic therapy will be successful. this study is being carried out to see whether the antibiotic 'meropenem' (which is also known as merrem i.v.) provides protection from developing a pancreatic infection. this will be done by comparing the progress of patients who receive meropenem with those who receive a non-active placebo solution (a solution that does not contain any active medication). meropenem or placebo would be given in addition to the standard treatment received for pancreatitis. it is not known if meropenem will help prevent infections associated with necrotizing pancreatitis. approximately 240 patients will take part in this study. study participation will be carried out for up to 6 weeks, and patients will receive the study treatment up to a maximum of 21 days.


Eligibility criteria:
inclusion criteria: * diagnosis of necrotizing pancreatitis within 120 hours following onset of symptoms/first reported symptoms. * primary diagnosis to be confirmed by contrast-enhanced ct evidence of 30% necrosis of the pancreas. * or if \> or equal to 30% necrosis is not present or cannot be confirmed, a contrast enhanced ct scan showing extensive or multiple pancreatic fluid collections and pancreatic edema (balthazar grade e) with either c-reactive protein (crp). 120 mg/l or a mod score of \> 2 is acceptable. exclusion criteria: * received an investigational drug or device within 30 days prior to entering study. * received \> 48 hours of antibiotic therapy between onset of symptoms of pancreatitis and diagnosis of necrotizing pancreatitis. * the subject has known or suspected anaphylactic or other type 1 (immediate) hypersensitivity reactions to cephalosporins, penicillins or carbapenems. * the subject is receiving, or will require, probenecid therapy. * the subject is neutropenic (absolute neutrophil count \< 1000/mm 3). * the subject has cirrhosis, severity of child's grade c. * there is not a commitment on the part of the clinical care team, the subject, or the subject's family to full, aggressive support including operative intervention if needed. * the subject is a pregnant and/or nursing female

Keywords: non-infected necrotizing pancreatitis pancreatic infection peripancreatic infection
dry needling versus magnesium sulphate iontophoresis in subjects with chronic mechanical neck pain

Conditions: Chronic Pain

Summary: the aim of this trial is to compare dry needling and magnesium sulphate iontophoresis in subjects with mechanical neck pain

mechanical neck pain is a prevalent condition in various populations. neck pain occurrence is affected by several factors, involving environmental, psychological, and social aspects. neck pain represents the fourth major disorder responsible for a person's year lived with disability and ranked eleventh as disability-adjusted life years of a person. the neck pain incidence ranges from 10.4 to 23.3% in 1-year time, while the range of prevalence was 0.4 to 86.8%. it has a high prevalence among computer users, office workers, and females, especially females aged 35 to 49 years old. myofascial trigger point (mtrp) might play an important role in the formation of mechanical neck pain and is known as a hyperirritable spot in skeletal muscle that is accompanied with a hypersensitive palpable nodule in a taut band. dry needling and iontophoresis play a major role in the treatment of mechanical neck pain so this trial was conducted to determine which one has superiority. this trial has three groups. two experimental and one control group.pain, function, pressure pain threshold and emg will be measured

Eligibility criteria:
inclusion criteria: all patients had active trigger myofascial trigger points (mtrps) in upper trapeziues muscle in the dominant side with mechanical neck pain. the patients age ranged from 18-35years the patients had been choosen from both sexes . patient agrees not to receive additional treatment for their painful condition during the trial (apart from nsaids and pain killers the patients body mass index \< 30 kg/m² exclusion criteria: history of whiplash injury history of cervical spine surgery cervical radiculopathy or myelopathy having undergone physical therapy within the past 3 months before the study. non -rheumatologic diseases as multiple sclerosis , thyroid dysfunction and chronic infection

Keywords: dry needling, iontophoresis, neck pain
efficacy and safety of posiformin 2 % eye ointment in the treatment of blepharitis

Conditions: Blepharitis; Signs and Symptoms

Summary: this is a multicentre, randomised, double-masked, parallel-group, phase iv comparison of posiformin 2 % eye ointment (active substance: bibrocathol) in the treatment of blepharitis.

reduction of signs and symptoms of blepharitis

Eligibility criteria:
inclusion criteria: * written informed consent * ambulatory male and female patients 18 years of age or older * summarised score of signs and symptoms of blepharitis of 15 or more at baseline exclusion criteria: * different ocular conditions * different system conditions * several concomitant medications

Keywords: bibrocathol eye ointment blepharitis eye lid
comparative clinical trial of efficacy and safety of bcd-055 and remicade® in combination with methotrexate in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: bcd-055-3 is international multi-center comparative double-blind randomized clinical trial of efficacy and safety of bcd-055 (jsc "biocad", russia) and remicade® in combination with methotrexate in patients with active rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * signed informed consent * active rheumatoid arthritis according to criteria of american college of rheumatologists (2010), that was diagnosed at least 6 months prior to screening. * active rheumatoid arthritis at screening despite of therapy with methotrexate for 3 last months. * use of methotrexate in stable dose for at least 4 weeks before screening (10-25 mg per week). * history of ineffective treatment with basic antiinflammatory drugs (including methotrexate). exclusion criteria: * previous therapy of rheumatoid arthritis with monoclonal antibodies (including anti-tumor necrosis factor drugs) * felty's syndrome * functional status - class iv according to acr classification (1991) * low activity of rheumatoid arthritis (das28-crp(4) index less than 3.2) * patient needs corticosteroids in a dose more than 10 mg (recalculated to prednisolone) before signing informed consent. * patients needs equal of less than 10 mg prednisolone but the dose was not stable for last 4 weeks prior to infliximab treatment * prior use of disease-modifying antirheumatic drugs including methotrexate, sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before randomization. * prior use of alkylating agents for up to 12 months prior to signing informed consent. * intraarticular use of corticosteroids for up to 4 weeks before randomization. * prior use of live or attenuated vaccines for up to 8 weeks before signing informed consent. * diagnosis of tuberculosis. * body mass more than 130 kg.
comparative utility of clinical balance measures in traumatic brain injury

Conditions: Traumatic Brain Injury; Acquired Brain Injury; Accidental Falls

Summary: the purpose of this research study is to investigate how useful three balance tests are in predicting fall risk in the individual with traumatic brain injury (tbi). these tests are the functional gait assessment (fga), the berg balance scale (bbs), and the mini-balance evaluation systems test (mini-bestest).

the purpose of the proposed study is to investigate the reliability and predictive validity of three balance measures, the berg balance scale (bbs), the functional gait assessment (fga) and the mini-balance evaluation systems test (mini-bestest), among individuals with history of traumatic brain injury. participants will complete a health history questionnaire and six-month fall history. when available, fall history will be corroborated with a family member that resides with the participant. participants will complete the montreal cognitive assessment. each participant will then participate in a 45-minute evaluation using the three performance-based outcome measures, with order randomized, with two blinded assessors. six and 12 month follow-up of number of falls will occur via telephone. statistical analysis with investigate the inter-rater reliability, predictive validity of fall risk and to determine cut off scores for fallers vs. non fallers in the population.

Eligibility criteria:
inclusion criteria: * community dwelling * medically stable * able to stand at least one minute unsupported (with/without assistive device) * able to ambulate 20 feet (with/without assistance or assistive device) * able to follow one step instructions or visual demonstrations. exclusion criteria: * presence of partial or non-weight bearing on a lower extremity

Keywords: fall risk rehabiliation physical therapy functional gait assessment mini-balance evaluation systems test berg balance scale psychometric properties validity inter-rater reliability montreal cognitive assessment
randomized clinical trial of treatment for temporomandibular joint (tmj) disc displacement

Conditions: Herniated Disk; Temporomandibular Disorders

Summary: the effectiveness of physical therapy for treatment of anterior disc displacement without reduction of temporomandibular disorders has not been well defined. this study compared the treatment method with conservative splint therapy. fifty two subjects were assigned at random to either of two treatment groups: one is a splint treatment group, and the other is a joint mobilization self exercise group. each treatment was evaluated using four outcome variables: (i) maximum mouth opening range without and (ii) with pain, (iii) present pain intensity, and (iv) limitation of daily activities. all outcome variables were significantly improved after eight-week of treatment in the exercise group. meanwhile, the splint treatment improved three variables, other than "mouth opening with pain"; however, the degree of improvement was less than that seen in the exercise group. this result demonstrates that the joint mobilization self exercise improves jaw function and relieves pain as compared to the splint treatment.


Eligibility criteria:
inclusion criteria: * (1) male or female over 18 years old; * (2) with mouth opening pain on the tmj affected side; * (3) over two weeks after the onset of addwor; * (4) with maximum mouth opening of less than 40 mm; and * (5) mri-confirmed addwor. the exclusion criteria: * (1) unwilling or unable to receive splint and/or exercise therapy; * (2) with systemic bone or joint disease, * (3) regular medication such as analgesics, anti-anxiety drugs, antidepressants and psychotropics; and * (4) missing teeth and/or a removable denture but having a fixed partial denture restoration over one year.

Keywords: anterior disc displacement without reduction of temporomandibular disorders